We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > DaxibotulinumtoxinA

News List

Ajinomoto Bio-Pharma and Revance Therapeutics Partner contractpharma
December 23, 2020
Ajinomoto Bio-Pharma Services and Revance Therapeutics Inc. have signed a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for Injection.
FDA defers approval of DaxibotulinumtoxinA for Injection in glabellar lines due to Covid-19 related travel restrictions pharmaceutical-business-review
November 30, 2020
Revance Therapeutics announced that the United States (U.S.) Food and Drug Administration (FDA) has deferred a decision on the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the ...